UCB Unveils Groundbreaking Findings on BIMZELX for Hidradenitis Suppurativa at AAD 2026 At the AAD 2026 Annual Meeting, UCB presented promising new data on BIMZELX, highlighting its long-term effectiveness in managing hidradenitis suppurativa symptoms over three years, impacting patient quality of life positively.

UCB Unveils Groundbreaking Findings on BIMZELX for Hidradenitis Suppurativa at AAD 2026 #None #UCB #BIMZELX #Hidradenitis_Suppurativa

UCB Showcases Groundbreaking Results for BIMZELX® in Treating Psoriasis at AAD 2026 UCB unveiled promising data for BIMZELX® (bimekizumab-bkzx) at AAD 2026, revealing significant effectiveness in achieving skin clearance for psoriasis patients.

UCB Showcases Groundbreaking Results for BIMZELX® in Treating Psoriasis at AAD 2026 #USA #Denver #UCB #Psoriasis #BIMZELX

BIMZELX® Outperforms SKYRIZI® in Groundbreaking Psoriatic Arthritis Study UCB's BIMZELX® (bimekizumab) demonstrates superior efficacy compared to SKYRIZI® (risankizumab) in reducing disease activity in patients with active psoriatic arthritis.

BIMZELX® Outperforms SKYRIZI® in Groundbreaking Psoriatic Arthritis Study #United_States #Atlanta #BIMZELX #Skyrizi #Psoriatic_Arthritis

UCB、HS第3相BE HEARDの3年データをEHSFで発表へ──BIMZELXで炎症性病変完全消失40.1％ | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

UCB showcases three-year hidradenitis suppurativa data at EHSF; BIMZELX (bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements

stellanews.life/technology/8...

#HidradenitisSuppurativa #HS #Bimekizumab #BIMZELX #EHSF #Phase3

Bimzelx for psoriatic arthritis Fred's journey

Just updated my thread on @psoriasisclub.com forum after three years on #Bimzelx for psoriatic arthritis & I'm still very happy.

Read more here if you're interested.

psoriasisclub.org/thread-7668-...

BIMZELX® Shows Significant Long-Term Efficacy in Treating Hidradenitis Suppurativa Pain and Lesions Recent data highlight BIMZELX's sustained effectiveness in relieving pain and resolving draining tunnels for patients with hidradenitis suppurativa over three years.

BIMZELX® Shows Significant Long-Term Efficacy in Treating Hidradenitis Suppurativa Pain and Lesions #USA #Atlanta #UCB #BIMZELX #Hidradenitis_Suppurativa

UCB Unveils Three-Year Data on BIMZELX, Indicating Long-Term Control of Inflammation in PsA and AxSpA Patients UCB has announced promising three-year findings on BIMZELX, showcasing sustained inflammation control in patients with psoriatic arthritis and axial spondyloarthritis, enhancing their quality of life.

UCB Unveils Three-Year Data on BIMZELX, Indicating Long-Term Control of Inflammation in PsA and AxSpA Patients #United_States #Atlanta #PSA #BIMZELX #AxSpA

BIMZELX® Shows Promising Long-Term Efficacy for Plaque Psoriasis at EADV New data from UCB reveals that nearly half of psoriasis patients sustained complete skin clearance with BIMZELX® over four years, offering hope for long-term management of the disease.

BIMZELX® Shows Promising Long-Term Efficacy for Plaque Psoriasis at EADV #USA #Atlanta #UCB #Psoriasis #BIMZELX

New Three-Year Data for BIMZELX® Demonstrates Long-Term Relief in Hidradenitis Suppurativa Treatment Recent studies reveal that BIMZELX® provides sustained symptom relief for hidradenitis suppurativa over three years, impacting patients' quality of life significantly.

New Three-Year Data for BIMZELX® Demonstrates Long-Term Relief in Hidradenitis Suppurativa Treatment #USA #Atlanta #UCB #BIMZELX #Hidradenitis_Suppurativa

UCB HS Summit: Uniting Patients and Experts for Hidradenitis Suppurativa Awareness and Treatment The 2025 UCB HS Summit gathered over 100 stakeholders to discuss Hidradenitis Suppurativa, highlighting patient voices, treatment needs, and raising awareness.

UCB HS Summit: Uniting Patients and Experts for Hidradenitis Suppurativa Awareness and Treatment #USA #Atlanta #UCB #BIMZELX #Hidradenitis_Suppurativa

UCB Launches Expanded Campaign to Support Hidradenitis Suppurativa Awareness with BIMZELX® UCB's campaign aims to educate the hidradenitis suppurativa community about treatment options like BIMZELX, empowering patients to talk with healthcare providers.

UCB Launches Expanded Campaign to Support Hidradenitis Suppurativa Awareness with BIMZELX® #UCB #BIMZELX #Hidradenitis_Suppurativa

Promising Three-Year Results of BIMZELX® in Treating Psoriatic Arthritis and Axial Spondyloarthritis Unveiled at EULAR 2025 Recent data from UCB's BIMZELX® show sustained efficacy in managing psoriatic arthritis and axial spondyloarthritis over three years, highlighting its therapeutic potential.

Promising Three-Year Results of BIMZELX® in Treating Psoriatic Arthritis and Axial Spondyloarthritis Unveiled at EULAR 2025 #None #Barcelona #BIMZELX #Psoriatic_Arthritis #Axial_Spondyloarthritis

BIMZELX® Shows Promising Two-Year Results in Treating Hidradenitis Suppurativa at AAD 2025 New two-year data from the AAD 2025 reveals BIMZELX® significantly reduces draining tunnels in hidradenitis suppurativa patients, improving quality of life substantially.

BIMZELX® Shows Promising Two-Year Results in Treating Hidradenitis Suppurativa at AAD 2025 #USA #Orlando #UCB #BIMZELX #Hidradenitis_Suppurativa

BIMZELX® Five-Year Data Show Sustained Efficacy in Psoriasis Treatment at AAD 2025 At AAD 2025, impressive five-year data on BIMZELX® reveal sustained skin clearance and long-term efficacy for moderate-to-severe psoriasis patients, showcasing notable results.

BIMZELX® Five-Year Data Show Sustained Efficacy in Psoriasis Treatment at AAD 2025 #USA #Orlando #UCB #Psoriasis #BIMZELX

UCB's Remarkable Growth in 2024 Showcases Strong Product Launch Performance UCB achieved impressive financial milestones in 2024, achieving significant revenue and net sales growth driven by successful product launches and a robust pipeline.

UCB's Remarkable Growth in 2024 Showcases Strong Product Launch Performance #UCB #Brussels #Belgium #FINTEPLA #BIMZELX

Bimekizumab shows long-term efficacy in hidradenitis suppurativa - PharmaTimes UCB's BIMZELX reveals promising two-year data at EHSF 2025

#Bimekizumab #hidradenitissuppurativa #dermatology #UCB #UCBPharma #BIMZELX #EHSF2025 #BEHEARDtrials #HiSCR75responders #interleukin17Ainhibitor #IL17Ainhibitor #interleukin17Finhibitor #IL17Finhibitor #EuropeanHidradenitisSuppurativaFoundation #HSpatients
pharmatimes.com/news/bimekiz...

UCB Launches New 320 mg Single-Injection Option for BIMZELX in the U.S. UCB introduces a new 320 mg single-injection option for BIMZELX, enhancing treatment accessibility for chronic inflammation patients in the U.S.

UCB Launches New 320 mg Single-Injection Option for BIMZELX in the U.S. #United_States #Atlanta #UCB #BIMZELX #bimekizumab

FDA approves Bimzelx for adults with moderate to severe hidradenitis suppurativa The FDA has approved Bimzelx for the treatment of moderate to severe hidradenitis suppurativa in adults, UCB announced in a press release. This approval makes Bimzelx (bimekizumab-bkzx, UCB) the first...

The @fda.gov has approved #Bimzelx for the treatment of moderate to severe hidradenitis suppurativa in adults.

This approval makes Bimzelx (bimekizumab-bkzx, UCB) the first and only approved interleukin-17F and -17A inhibitor in this indication.

www.healio.com/news/dermato...